Respiratory Inhaler Device Market Size

  • Report ID: 202
  • Published Date: Dec 23, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2025-2037

Respiratory Inhaler Device Market size was valued at USD 38.85 billion in 2024 and is likely to cross USD 71.46 billion by 2037, expanding at more than 4.8% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of respiratory inhaler device is estimated at USD 40.44 billion.

The growth of the market can be attributed to increasing cases of chronic obstructive pulmonary diseases. Furthermore, the data published by the World Health Organization states that asthma affected 262 million people in 2019 and caused 455,000 deaths worldwide. The inhaled medication can control asthma symptoms, which is the reason global market is projected to grow significantly during the forecast period. Additionally, the prevalence of chronic obstructive pulmonary diseases is directly related to tobacco smoking. The data released by the Institutes for Health Metrics and Evaluation states that the number of smokers is rising worldwide and in 2019, smoking caused 8 million deaths. On the back of an escalating number of people involved in smoking the market is estimated to grow significantly during the forecast period. The inhalers are effective in providing relief to common cold patients. On account of the efficacy in providing relief to common cold patients, the respiratory inhaler device market is projected to grow during the forecast period.



Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of respiratory inhaler device is estimated at USD 40.44 billion.

Respiratory Inhaler Device Market size was valued at USD 38.85 billion in 2024 and is likely to cross USD 71.46 billion by 2037, expanding at more than 4.8% CAGR during the forecast period i.e., between 2025-2037.

North America industry is predicted to dominate majority revenue share by 2037, on the back of presence of a highly established healthcare infrastructure.

The major players in the market are Merck & Co., Inc., GlaxoSmithKline plc., Cipla Inc., and Koninklijke Philips N.V.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos